Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells

Biochemical Pharmacology

Volumn 63, Issue 10, 2002, Pages 1807-1815

  Willmore, Elaine ^a   Errington, Fiona ^a   Tilby, Michael J ^a   Austin, Caroline A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Cleavable complex; DNA topoisomerase II; Idarubicin; K562 cells; Leukaemia; TARDIS

Indexed keywords

2,3 BIS(3,5 DIOXO 1 PIPERAZINYL)BUTANE; ACLARUBICIN; AGAROSE; AMSACRINE; ANTHRACYCLINE DERIVATIVE; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; DRUG METABOLITE; ENZYME ANTIBODY; ETOPOSIDE; IDARUBICIN; IDARUBICINOL; ISOENZYME; MITOXANTRONE;

ANIMAL CELL; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLYSIS; DNA DETERMINATION; DRUG CYTOTOXICITY; DRUG POTENCY; ENZYME DEGRADATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LEUKEMIA CELL; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; CATALYTIC DOMAIN; DAUNORUBICIN; DNA; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IDARUBICIN; K562 CELLS; LEUKEMIA;

EID: 0037094408     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)00920-6     Document Type: Article

References (42)

1. AML Collaborative Group, A systematic collaborative overview of randomised trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia
2. Clinical applications of anticancer drugs targeted to topoisomerase II
3. The use of an oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukaemia in the elderly: A report of toxicity and efficacy
4. Idarubicin: A brief overview on pharmacology and clinical use
5. Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells
6. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, dainorubicin, 8-(S)-fluoroidarubicin and idarubicin in multidrug-resistant K562 cells
7. P-glycoprotein in primary acute myeloid leukaemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy
8. Correlation between the kinetics of anthracycline uptake and the resistance factor in cancer cells expressing the multidrug resistance protein or the P-glycoprotein
9. The relative importance of passive and P-glycoprotein mediated anthracycline efflux from multidrug-resistant cells
10. Human DNA topoisomerase IIα-dependent DNA cleavage and yeast cell killing by anthracycline analogues
11. A critical evaluation of the mechanisms of action proposed for the antitumour effects of the anthracycline antibiotics adriamycin and daunorubicin
12. Eukaryotic DNA topoisomerase IIβ
13. DNA topoisomerase II as the primary target of antitumour anthracyclines
14. Topoisomerase II as a target for anticancer drugs: When enzymes stop being nice
15. A prospective randomized trial of idarubicin vs. Daunorubicin in combination chemotherapy for acute myelogenous leukaemia of the age group 55-75
16. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukaemia
17. Etoposide targets topoisomerase IIα and IIβ in leukaemic cells: Isoform-specific cleavable complexes visualised and quantified in situ by a novel immunofluorescence technique
18. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukaemia during therapy
19. DNA topoisomerase IIβ and neural development
20. Murine transgenic cells lacking DNA topoisomerase IIβ are resistant to acridines and mitoxantrone: Analysis of cytotoxicity and cleavable complex formation
21. Nuclear distribution of human DNA topoisomerase IIβ: A nuclear targeting signal resides in the 116-residue C-terminal tail
22. Synergistic enhancement of 6-thioguanine cytotoxicity by ADP-ribosyltransferase inhibitors
23. Potentiation of temozolamide-induced cytotoxicity: A comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors
24. Detection and quantification of melphalan-DNA adducts at the single cell level in hematopoietic tumour cells
25. The combination of different types of antitumour topoisomerase II inhibitors, ICRF-193 and VP-16, has synergistic and antagonistic effects on cell survival, depending on treatment schedule
26. A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines
27. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle
28. Cytotoxicity of anthracyclines: Correlation with cellular uptake, intracellular distribution and DNA binding
29. Anthracyclines and their C-13 metabolites: Growth inhibition and DNA damage following incubation with human tumor cells in culture
30. Effect of PSC 833 on the cytotoxicity of idarubicin and idarubicinol in multidrug-resistant K562 cells
31. Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer
32. Relationships between lethal effects and topoisomerase II-mediated double-stranded DNA breaks produced by anthracyclines with different sequence specificity
33. Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human TOP2β construct allows the study of topoisomerase IIβ inhibitors in yeast
34. Ultraviolet-induced DNA damage stimulates topoisomerase I-DNA complex formation in vivo: Possible relationship with DNA repair
35. Cell death induced by topoisomerase-targeted drugs: More questions than answers
36. Drug sensitivity and sequence specificity of human recombinant DNA topoismerase IIα(p170) and IIβ(p180)
37. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance
38. Role of DNA breakage in cytotoxicity of doxorubicin, 9-deoxydoxorubicin, and 4-demethyl-6-deoxydoxorubicin in murine leukaemia P388 cells
39. Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4′-(9-acridinylamino)methanesulfon-m-anisidide and adriamycin
40. Formation, resealing and persistance of DNA breaks produced by 4-demethoxydaunorubicin in P388 leukaemia cells
41. Single-strand DNA breaks induced by chromophore-modified anthracyclines in p388 leukaemia cells
42. Intercalative antitumour drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II